<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ADRENALINE/EPINEPHRINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ADRENALINE/EPINEPHRINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cardiopulmonary resuscitation</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 mg every 3&#8211;5 minutes as required, a 1 in 10000 (100 micrograms/mL) solution is recommended.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute hypotension</span>,
            </h4>
            <p class="specificity"><span class="route">By continuous intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children </strong><br/>
                Initially 100 nanograms/kg/minute (max. per dose 1.5 micrograms/kg/minute), adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Emergency treatment of acute anaphylaxis (specialist use only)</span>,
                <span class="indication">Angioedema (if laryngeal oedema is present) (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the thigh, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function.</li>
              <li class="dose child"><strong>For children 1 month&#8211;5 years</strong><br/>
                150 micrograms, repeated if necessary, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, suitable syringe to be used for measuring small volume; injected preferably into the anterolateral aspect of the middle third of the thigh.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                300 micrograms, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, to be injected preferably into the anterolateral aspect of the middle third of the thigh.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                500 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the thigh, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, 300 micrograms (0.3 mL) to be administered if child small or prepubertal.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute anaphylaxis when there is doubt as to the adequacy of the circulation (specialist use only)</span>,
                <span class="indication">Angioedema (if laryngeal oedema is present) (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 micrograms, using 0.01 mL/kg of the dilute 1 in 10 000 adrenaline injection, dose to be repeated according to response, if multiple doses required, adrenaline should be given as a slow intravenous infusion stopping when a response has been obtained.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Control of bradycardia in patients with arrhythmias after myocardial infarction, if there is a risk of asystole, or if the patient is unstable and has failed to respond to atropine</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2&#8211;10 micrograms/minute, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Priapism associated with alprostadil, if aspiration and lavage of corpora are unsuccessful (alternative to phenylephrine or metaraminol)</span>,
            </h4>
            <p class="specificity"><span class="route">By intracavernosal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;20 micrograms every 5&#8211;10 minutes, using a 20 microgram/mL solution, Important: if suitable strength of adrenaline not available may be specially prepared by diluting 0.1 mL of the adrenaline 1 in 1000 (1 mg/mL) injection to 5 mL with sodium chloride 0.9%, continuously monitor blood pressure and pulse; maximum 100 micrograms per course.</li>
            </ul>
          </section>
        </section>
        
        
        
        
            <section class="pharmacokinetics">
              <h3>Pharmacokinetics</h3>
              <p>The effects of nebulised adrenaline for the treatment of croup lasts for 2&#8211;3 hours.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Acts on both alpha and beta receptors and increases both heart rate and contractility (beta<sub>1</sub> effects); it can cause peripheral vasodilation (a beta<sub>2</sub> effect) or vasoconstriction (an alpha effect).</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>May reduce placental perfusion and cause tachycardia, cardiac irregularities, and extrasystoles in fetus.</p><p>Can delay second stage of labour.</p><p>Manufacturers advise use only if benefit outweighs risk.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturers advise use with caution in severe impairment.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Angina, angle-closure glaucoma, anorexia, anxiety, arrhythmias, cold extremities, confusion, difficulty in micturition, dizziness, dry mouth, dyspnoea, headache, hyperglycaemia, hypersalivation, hypertension (risk of cerebral haemorrhage), hypokalaemia, insomnia, metabolic acidosis, mydriasis, myocardial infarction, nausea, pallor, palpitation, psychosis, pulmonary oedema (on excessive dosage or extreme sensitivity), restlessness, sweating, tachycardia, tissue necrosis at injection site, tissue necrosis of bowel, tissue necrosis of extremities, tissue necrosis of kidneys, tissue necrosis of liver, tremor, urinary retention, vomiting, weakness,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
                <p class="title">Acute hypotension</p>
              <p>For <i>continuous intravenous infusion</i>, dilute with Glucose 5% or Sodium Chloride 0.9% and give through a central venous catheter. Incompatible with bicarbonate and alkaline solutions.</p><p>
            <i>Neonatal intensive care</i>, dilute 3&#8239;mg/kg body-weight to a final volume of 50&#8239;mL with infusion fluid; an intravenous infusion rate of 0.1&#8239;mL/hour provides a dose of 100&#8239;nanograms/kg/minute; infuse through a central venous catheter. Incompatible with bicarbonate and alkaline solutions.</p><p>These infusions are usually made up of adrenaline 1 in 1000 (1&#8239;mg/mL) solution.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph> in children</h3>
              <p>For nebulisation in croup, dilute adrenaline 1 in 1000 solution with sterile sodium chloride 0.9% solution.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
                <p class="title">Cardiopulmonary resuscitation</p>
              <p>Administration through a central line results in a faster response than peripheral administration, however placement of a central line must not interfere with chest compressions; drugs administered peripherally must be followed by a flush of at least 20&#8239;mL Sodium Chloride 0.9% injection to aid entry into the central circulation. </p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Individuals at considerable risk of anaphylaxis need to carry (or have available) adrenaline at all times and the patient, or their carers, need to be <i>instructed in advance</i> when and how to inject it.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Adrenaline auto-injector for anaphylaxis</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/adrenaline-for-anapylaxis">www.medicinesforchildren.org.uk/adrenaline-for-anapylaxis</xref>
            </p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Safe Practice</h3>
              <p>Intravenous route should be used with <b>extreme care</b> by specialists only.</p>
            </section>
            <section class="importantSafetyInformation">
              <h3 class="specificity">When used by <ph outputclass="route">local infiltration</ph> in adults</h3>
                <p class="title">Use as a vasoconstrictor in local anaesthesia</p>
              <p>Local anaesthetics cause dilatation of blood vessels. The addition of a vasoconstrictor such as adrenaline (epinephrine) to the local anaesthetic preparation diminishes local blood flow, slowing the rate of absorption and thereby prolonging the anaesthetic effect. Great care should be taken to avoid inadvertent intravenous administration of a preparation containing adrenaline, and it is not advisable to give adrenaline with a local anaesthetic injection in digits or appendages because of the risk of ischaemic necrosis.</p><p>Adrenaline must be used in a low concentration when administered with a local anaesthetic. The total dose of adrenaline should not exceed 500&#8239;micrograms and it is essential not to exceed a concentration of 1 in 200 000 (5&#8239;micrograms/mL) if more than 50&#8239;mL of the mixture is to be injected. Care must also be taken to calculate a safe maximum dose of local anaesthetic when using combination products.</p><p>In patients with severe hypertension or unstable cardiac rhythm, the use of adrenaline with a local anaesthetic may be hazardous. For these patients an anaesthetic without adrenaline should be used.</p>
            </section>
            <section class="importantSafetyInformation">
              <h3 class="specificity">When used by <ph outputclass="route">local infiltration</ph> in children</h3>
                <p class="title">Use as a vasoconstrictor in local anaesthesia</p>
              <p>Local anaesthetics cause dilatation of blood vessels. The addition of a vasoconstrictor such as adrenaline (epinephrine) to the local anaesthetic preparation diminishes local blood flow, slowing the rate of absorption and thereby prolonging the anaesthetic effect. Great care should be taken to avoid inadvertent intravenous administration of a preparation containing adrenaline, and it is not advisable to give adrenaline with a local anaesthetic injection in digits or appendages because of the risk of ischaemic necrosis.</p><p>Adrenaline must be used in a low concentration when administered with a local anaesthetic. The total dose of adrenaline should not exceed 5&#8239;micrograms/kg (1&#8239;mL/kg of a 1 in 200 000 solution) and it is essential not to exceed a concentration of 1 in 200 000 (5&#8239;micrograms/mL) if more than 50&#8239;mL of the mixture is to be injected. Care must also be taken to calculate a safe maximum dose of local anaesthetic when using combination products.</p><p>In children with severe hypertension or unstable cardiac rhythm, the use of adrenaline with a local anaesthetic may be hazardous. For these children an anaesthetic without adrenaline should be used.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>:</strong>
            Arteriosclerosis in adults
          </li>
          <li>
            arrhythmias
          </li>
          <li>
            cerebrovascular disease
          </li>
          <li>
            cor pulmonale
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
              <strong>:</strong>
            elderly in adults
          </li>
          <li>
            hypercalcaemia
          </li>
          <li>
            hyperreflexia
          </li>
          <li>
            hypertension
          </li>
          <li>
            hyperthyroidism
          </li>
          <li>
            hypokalaemia
          </li>
          <li>
            ischaemic heart disease
          </li>
          <li>
            obstructive cardiomyopathy
          </li>
          <li>
            occlusive vascular disease
          </li>
          <li>
            organic brain damage
          </li>
          <li>
            phaeochromocytoma
          </li>
          <li>
            prostate disorders
          </li>
          <li>
            psychoneurosis
          </li>
          <li>
            severe angina
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
        <ul>
          <li>
            <p>Cautions listed are only for non-life-threatening situations.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor blood pressure and ECG.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use for <ph outputclass="indication">acute anaphylaxis</ph> in children</h3>
              <p>Auto-injector delivering 150-microgram dose of adrenaline not licensed for use in children body-weight under 15&#8239;kg.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use for <ph outputclass="indication">acute hypotension</ph> in children</h3>
              <p>Adrenaline 1 in 1000 (1&#8239;mg/mL) solution is not licensed for intravenous administration.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>It is important, in acute anaphylaxis where intramuscular injection might still succeed, time should not be wasted seeking intravenous access.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <p>Great vigilance is needed to ensure that the <i>correct strength</i> of adrenaline injection is used; anaphylactic shock kits need to make a <i>very clear distinction</i> between the 1 in 10 000 strength and the 1 in 1000 strength.</p><p>Patients with severe allergy should be instructed in the self-administration of adrenaline by intramuscular injection.</p><p>Packs for self-administration need to be <b>clearly labelled with instructions</b> on how to administer adrenaline (intramuscularly, preferably at the midpoint of the outer thigh, through light clothing if necessary) so that in the case of rapid collapse someone else is able to give it. It is important to ensure individuals at risk and their carers understand that:</p><ul>
            <li>two injection devices should be carried at all times to treat symptoms until medical assistance is available; if, after the first injection, the individual does not start to feel better, the second injection should be given 5 to 15 minutes after the first;</li>
            <li>an ambulance should be called after every administration, even if symptoms improve;</li>
            <li>the individual should lie down with their legs raised (unless they have breathing difficulties, in which case they should sit up) andshould not be left alone.</li>
            </ul><p> Adrenaline for administration by intramuscular injection is available in &#8216;auto-injectors&#8217; (e.g. <i>Emerade</i>
            <tm tmtype="reg"/>, <i>EpiPen</i>
            <tm tmtype="reg"/>, or <i>Jext</i>
            <tm tmtype="reg"/>), pre-assembled syringes fitted with a needle suitable for very rapid administration (if necessary by a bystander or a healthcare provider if it is the only preparation available); injection technique is device specific. To ensure patients receive the auto-injector device that they have been trained to use, prescribers should specify the brand to be dispensed.</p>
            </section>
      </section>







      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <p>POM restriction does not apply to the intramuscular administration of up to 1&#8239;mg of adrenaline injection 1 in 1000 (1&#8239;mg/mL) for the emergency treatment of anaphylaxis.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ADRENALINE/EPINEPHRINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,
            liquid,
            eye drops,

            <div id="PHP77486"><a href="../medicinalForm/PHP77486.html" data-target="#PHP77486" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
